Abstract 164 Table 1

Cemiplimab vs Individual IC chemotherapy	Investigator choice chemotherapy prior to randomisation				
	Pemetrexed (n=119 vs 111)	Topotecan (n=20 vs 21)	Irinotecan (n=26 vs 19)	Gemcitabine (n=108 vs 121)	Vinorelbine (n=31 vs 32)
Median OS	12.5 (7.5–15.3) vs 7.7 (6.4–9.8) HR; 0.71 (0.52–0.98)	7.0 (3.9–15.0) vs 6.5 (4.4–8.8) HR; 0.78 (0.31–1.96)	15.8 (11.2–NE) vs 11.8 (6.9–14.9) HR; 0.69 (0.28–1.70)	10.7 (9.2–13.3) vs 9.0 (7.0–10.6) HR; 0.76 (0.54–1.06)	10.3 (3.4–22.8) vs 7.6 (5.2–13.2) HR; 0.77 (0.40–1.48)
Median PFS	3.0 (2.3–4.2) vs 2.9 (2.6–3.7) HR; 0.70 (0.52–0.94)	2.2 (1.3–4.1) vs 2.3 (1.7–5.4) HR; 0.90 (0.43–1.90)	6.9 (1.9–13.8) vs 4.2 (1.6–8.3) HR; 0.77 (0.34–1.72)	2.8 (2.6–4.3) vs 2.8 (2.1–3.9) HR; 0.73 (0.54–0.97)	1.5 (1.4–2.7) vs 2.8 (1.5–4.1) HR; 1.21 (0.70–2.09)
ORR	16.0 (9.9–23.8) vs 6.3 (2.6–12.6)	15.0 (3.2–37.9) vs 4.8 (0.1–23.8)	23.1 (9.0–43.6) vs 15.8 (3.4–39.6)	17.6 (10.9–26.1) vs 5.0 (1.8–10.5)	9.7 (2.0–25.8) vs 6.3 (0.8–20.8)
Data shown by individual investigator choice of chemotherapy selected prior to randomisation in cemiplimab versus chemotherapy arms. OS and PFS data shown as months, 95% CI; ORR data shown as %, 95% CI. CI, confidence interval; HR, hazard ratio; NE, not evaluable.					

chosen prior to randomisation. Adult females (age ≥ 18 years) were enrolled regardless of PD-ligand 1 expression and received cemiplimab 350 mg intravenously every 3 weeks or IC chemotherapy for up to 96 weeks; and were stratified by histology (squamous cell carcinoma/adenocarcinoma or adenosquamous), geographic region (North America/Asia/rest of world), prior bevacizumab, and ECOG performance status (0/1). Primary endpoint was OS. Additional endpoints included progression-free survival (PFS), objective response rate (ORR), duration of response, quality of life and safety. Data cutoff was 4 January 2021.

Result(s)* A total of 608 patients were randomised: 304 to cemiplimab and 304 to IC chemotherapy (gemcitabine, n=121; pemetrexed, n=111; vinorelbine, n=32; topotecan, n=21; irinotecan, n=19) across geographic regions and histologies. Median duration of study follow-up (range) was 4.8 months (0.0–25.9) for the overall population. At second interim analysis, the trial was stopped early for efficacy. OS, PFS and ORR (table 1) demonstrated improvements with cemiplimab vs each IC chemotherapy treatment similar to those observed with cemiplimab vs pooled IC chemotherapy.

Conclusion* Improvements in OS, PFS and ORR with cemiplimab trended consistently with the results for the overall population regardless of IC chemotherapy drug.

171

DYNAMIC DOSE FRACTIONATION OF HDR-BRACHYTHERAPY AT PREOPERATIVE IRRADIATION OF CERVICAL CANCER PATIENTS

V Sukhin*, H Hranovska, O Sukhina, K Nemaltsova. Grigoriev Institute for medical Radiology and Oncology NAMS of Ukraine, Oncogynecology, Kharkov, Ukraine

10.1136/ijgc-2021-ESGO.15

Introduction/Background* The direct influence of irradiation on cervical cancer can be realized by brachytherapy (BT). We have developed methodic of dynamic dose fractionation of brachytherapy, which determined the relevance of this investigation.

The aim of this study is efficacy improvement of combined treatment of cervical cancer patients, by application of high dose-rate brachytherapy (HDR) by the method of dynamic dose fractionation as a first step of preoperative course of radiochemotherapy.

Methodology There were enrolled 54 cervical cancer patients with primary stages IB – IIA (T1b-2aNxM0). All the patients were divided into 2 groups. BT was performed by device «MultiSource», and external beam radiation therapy (EBRT) – by «Clinac 600C», with chemomodification agent cisplatin 40 mg/m² weekly.

Group 1 included 34 patients, whose treatment was started with two sessions of BT (step 1) – the first one with single dose of 7 Gy, the second one – of 5 Gy, and then EBRT (20 Gy) up to the total dose of 32/23 Gy (step 2).

Group 2 included 20 patients, whose treatment was started with EBRT (20 Gy) – step 1, with sequential two sessions of BT with each single dose of 5 Gy (step 2), up to the total dose of 30/22.5 Gy.

The follow-up period was 3-26 months, mean – 17.2 months.

Result(s)* The effectiveness of dynamic dose fractionation HDR-BT was proved by complete tumor regression (pathomorphosis grade IV) in 35.3% of 34 patients: 50.0% of stage IB patients and 36.4% – stage IIA. In group 2, there was detected only partial tumor regression (pathomorphosis of grade II-III) in all the patients. The relapsed disease was detected in 1 (6.7%) patient of Group 2 at follow-up before 1 year.

Conclusion* Dynamic dose fractionation HDR-brachytherapy, as 1st step of preoperative chemo-irradiation, allows to reach the total tumor regression, which enable further ablative surgery and relapse-free follow-up.

199

RANDOMISED PHASE II BGOG/ENGOT-CX1 STUDY OF PACLITAXEL-CARBOPLATIN WITH OR WITHOUT NINTEDANIB IN FIRST-LINE RECURRENT OR ADVANCED CERVICAL CANCER

¹IB Vergote*, ²E Van Nieuwenhuysen, ³A Casado, ⁴A Laenen, ⁵D Lorusso, ⁶I Braicu, ⁷E Guerra-Alia, ⁸P Zola, ⁹P Wimberger, ¹⁰P Debruyne, ¹¹E Falcó, ¹²A Ferrero, ¹³MZ Muallem, ¹⁴J Kerger, ¹⁵E García Martínez, ¹⁶S Pignata, ¹⁷J Sehouli, ¹⁸T Van Gorp, ¹⁹C Gennigens, ²⁰MJ Rubio Pérez. ¹University Hospitals Leuven, Belgium and BGOG, Belgium; ²University Hospitals Leuven, Belgium and BGOG; ³Hospital Clínico San Carlos, Madrid Spain and GEICO; ⁴Catholic University Leuven, Belgium; ⁵Policlinico Universitario Agostino Gemelli, Italy and ENGOT; ⁶Charité Universitätsmedizin Berlin and ENGOT; ⁷Hospital Ramón y Cajal, Madrid Spain and GEICO; ⁸University of Turin, Italy and ENGOT; ⁹Universitätsklinikum Carl Gustav Carus, Dresden, Germany and ENGOT; ¹⁰AZ Groeninge, Kortrijk, Belgium; ¹¹Hospital Son Llatzer, Palma de Mallorca, Spain and GEICO; ¹²Mauriziano Hospital, Torino, Italy and ENGOT; ¹³Charité Universitätsmedizin Berlin, Berlin, Germany; ¹⁴Institut Jules Bordet, Brussels, Belgium and BGOG; ¹⁵Hospital Universitario Morales Meseguer, Murcia Spain and GEICO; ¹⁶Instituto Nazionale Tumori, Napoli, Italy and ENGOT; ¹⁷Charité Universitätsmedizin Berlin, Berlin, Germany and ENGOT; ¹⁸University Hospital (CHU) of Liege, Belgium and BGOG; ¹⁹Hospital Universitario Reina Sofía, Córdoba, Spain and GEICO

10.1136/ijgc-2021-ESGO.16

Introduction/Background* Platinum in combination with paclitaxel (P) and bevacizumab is the standard of care in first-line recurrent/advanced cervical cancer (Tewari, NEJM 2020). Nintedanib is an oral tyrosine kinase inhibitor targeting, among others, vascular endothelial growth factor receptor.

Methodology Double-blind phase II randomised study in patients with first-line recurrent or primary advanced (FIGO stage IVB) cervical cancer. Patients received carboplatin AUC 5-6 and paclitaxel 175mg/m² q 3 weeks with oral nintedanib 200 mg BID/placebo. Stratification factor was primary advanced versus recurrent disease. The primary endpoint was progression-free survival (PFS) at 1,5 years with at least 87 events and $\alpha=0.15$, $\beta=80\%$, one sided, in favor of the nintedanib (N) versus control (C) arm. The study (NCT02009579) was performed according to the ENGOT model A.

Result(s)* 120 patients (62 N, 58 C) were randomised between March 2014 and October 2018. Median follow-up was 35 months. Baseline characteristics were similar in both groups (total population: squamous cell carcinoma 62%, prior radiotherapy 64%, primary advanced 25%, recurrent 75%). The primary endpoint was met with a PFS at 1.5 years of 15.1% versus 12.8% in favour of the nintedanib arm ($p = 0.057$). Median overall survival (OS) was 21.7 and 16.4 months for N and C, respectively. Subgroup analysis did not demonstrate a difference in PFS in the primary advanced setting, but in the recurrent setting the 1 year PFS was 22.8% and 14.9% for N and C, respectively. Confirmed RECIST response rate was 48% for N and 39% for C. No new adverse events were noted for N. However N was associated with numerically more serious adverse events for anemia and febrile neutropenia. Discontinuation of chemotherapy was similar in both groups. N was discontinued in 3% versus placebo in 1.6% of the patients. Dose reduction of N was necessary in 53% of the patients.

Conclusion* The study met its primary endpoint with a prolonged PFS in the N arm. No new safety signals were observed.

200

CAN METHYLATION SIGNALS OF CERVICAL CANCER ENHANCE CERVICAL SCREENING?: AN EPIGENOME-WIDE ASSOCIATION STUDY ON THE ILLUMINA 850K ARRAY

^{1,2}S Bowden*, ³B Bodinier, ⁴M Paraskevaidi, ¹I Kalliala, ⁵N Chaitrakulthong, ¹A Mitra, ¹M Tzafetas, ⁴K Lathouras, ⁶M Nasioutziki, ⁵J Flanagan, ³M Chadeau-Hyam, ^{2,4}M Kyrgiou. ¹Institute of Reproductive and Developmental Biology, Department of Surgery and Cancer – Metabolism, Digestion and Reproduction, UK; ²West London Gynaecological Cancer Centre, Hammersmith Hospital, London, UK; ³Imperial College London, School of Public Health, Biostatistics and Epidemiology, London; ⁴Imperial College London, Institute of Reproductive and Developmental Biology, Department of Surgery and Cancer – Metabolism, Digestion and Reproduction, UK; ⁵Imperial College London, Institute of Developmental and Reproductive Biology, Surgery and Cancer, London, UK; ⁶Aristotle University, Cytopathology, Thessaloniki, Greece

10.1136/ijgc-2021-ESGO.17

Introduction/Background* Cervical cancer is one of the most prevalent and leading cause of cancer mortality for women worldwide. Persistent infection with HPV is associated with the development of cervical cancer. Although most infections are cleared by the immune response, the factors related to persistent infection and carcinogenesis are less well understood. Epigenetic alterations are essential in the development of many cancers; while aberrant hypermethylation in cervical carcinogenesis has been identified in several targeted studies, epigenome-wide exploration has been limited. In this epigenome-wide association study (EWAS) we explore differential DNA methylation signatures associated to CIN3 and Cervical Cancer, to better understand potential drivers and biomarkers of cervical carcinogenesis.

Methodology 247 women (119 normal, 74 CIN3/CGIN and 54 cervical cancer) attending gynaecological appointments, cervical screening and oncological treatment between 2014-2020 at English and Greek referral hospitals were recruited. Methylation signatures were obtained following bisulphite conversion of DNA extracted from exfoliated cervical cells and sequenced using the Illumina 850k array data. After normalisation and data QC, mixed linear models and a penalised regression were used to test for independent associations between methylation CpG sites and case-control status. P-values were Bonferroni corrected and adjusted for batch, chip, age and HPV status.

Result(s)* 177 CpG sites were strongly associated with CIN3 or cervical cancer, as measured by a P -value $<5 \times 10^{-8}$ and a gain/loss in methylation of $>15\%$ between cases and controls. Epigenetic signals were located in over 141 unique genes genome-wide, with a gain in methylation in CIN3 or cancer cases being more common ($n=77/80$).

Conclusion* This is potentially the first adequately powered study to highlight genome-wide epigenetic signatures associated to carcinoma *in situ* and cervical cancer. This builds on previous genetic signals associated with cervical cancer identified by our group (Bowden *et al*, Lancet Oncol, 2021). While around 59 genes were previously reported associations to CIN or cervical cancer, the remaining 82 signals appear to be novel. Functional annotation highlighted several genes related to tumour suppressor function, transcription factors and apoptosis – important for cervical cancer tumorigenesis.